Clinical Research Directory

Inclusion Criteria: * Evidence of hepatic steatosis (≥ grade 1) at screening. * Body mass index (BMI) ≥25 kg/m² or presence of metabolic dysfunction consistent with MASLD diagnostic criteria. * Stable body weight (no significant weight change during the 3 months preceding enrollment). * Willingness to maintain usual dietary habits, physical activity, and concomitant medications throughout the study. * Ability to provide written informed consent. Exclusion Criteria: * Excessive alcohol consumption (\>30 g/day for men or \>20 g/day for women). Other known causes of chronic liver disease, including viral hepatitis (HBV or HCV), autoimmune liver disease, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, or drug-induced liver disease. * Evidence of liver cirrhosis, hepatic decompensation, hepatocellular carcinoma, or other severe liver disorders. * Previous bariatric surgery or planned bariatric surgery during the study period. * Current use of medications or nutritional supplements known to significantly affect hepatic steatosis or liver function unless on a stable dose for at least 3 months before enrollment. * Pregnancy or breastfeeding. * Severe renal, cardiovascular, respiratory, endocrine, or malignant disease that could interfere with study participation. * Known allergy or hypersensitivity to silybin, glutathione, vitamin E, or any component of the study product. * Any condition that, in the investigator's judgment, could compromise participant safety or adherence to the study protocol